High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C

Citation
V. Di Marco et al., High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C, ALIM PHARM, 15(7), 2001, pp. 953-958
Citations number
30
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Pharmacology,"da verificare
Journal title
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
ISSN journal
0269-2813 → ACNP
Volume
15
Issue
7
Year of publication
2001
Pages
953 - 958
Database
ISI
SICI code
0269-2813(200107)15:7<953:HPCTIN>2.0.ZU;2-U
Abstract
Background: Therapy of chronic hepatitis C non-responders to interferon mon otherapy with standard doses of interferon plus ribavirin is usually ineffe ctive. Aim: To evaluate the efficacy and tolerability of high-dose prolonged combi nation retreatment in non-responder patients. Methods: Patients were retreated for 6 months with 6 MU alpha IFN on altern ate days and 1000 or 1200 mg/day ribavirin. HCV-RNA negative patients conti nued therapy for an additional 6 months. Results: Forty patients (29 males, mean age 49.7 years, 34 genotype 1b, 11 with F3 fibrosis) were treated. At 6 months, 20 (50%) patients were HCV-RNA negative but six of them discontinued therapy because of adverse events. A sustained response was achieved in 28% of patients (11/40). A sustained re sponse was more frequent among patients with genotype non-1b then in those with genotype 1b (67 vs. 21%, P = 0.005) and clearance of HCV-RNA in the fi rst 3 months had a high predictive value for sustained response (100% of su stained responders vs. 24% of non-responders, P = 0.0001). Conclusions: High-dose prolonged combination therapy in non-responders to I FN monotherapy leads to a higher rate of sustained response than the standa rd combination regimen. Tolerability may be a rate-limiting factor. Maximal effectiveness can be predicted in patients with non-1b genotype and in tho se who clear HCV-RNA soon after starting retreatment.